Japan’s ageing population is enormous. That does not automatically make Japan a good market for your product. The commercial question is more demanding: who will buy your solution, who will pay for it, what evidence will they require, and how will you reach them? Japan had 36.24 million people aged 65+ in October 2024, representing 29.3% of the population. More than 20 million were already 75+. Those numbers create real demand in healthcare, elderly care, rehabilitation, diagnostics, monitoring, dementia support and preventive health.
They do not create a route-to-market.
There is no single Japanese “elderly market”
A healthy 68-year-old in Yokohama, an 82-year-old living independently in rural Japan, a dementia patient in residential care and a hospital patient preparing for discharge have very different needs. So do the organisations surrounding them.
If you and your team are eyeing Japan’s Silver Economy, it becomes more useful when you divide it according to problem, buyer and payment route.
| Segment | Typical Japanese buyers or decision-makers | Possible payment route | Main commercial question |
|---|---|---|---|
| Medical devices, diagnostics and remote monitoring | Hospitals, clinics, nursing homes, home healthcare providers, distributors | National Health Insurance, institutional budgets, self-pay | Is there sufficient clinical and economic evidence? |
| Care technology and monitoring | Care groups, nursing homes, home-care providers, municipalities, equipment suppliers | Long-Term Care Insurance, subsidies, provider budgets | Does it reduce workload or improve quality of care? |
| Rehabilitation, mobility and fall prevention | Hospitals, rehabilitation centres, day-care operators, care providers | Medical insurance, Long-Term Care Insurance, provider budgets | Can you demonstrate measurable functional benefit? |
| Dementia and cognitive support | Care providers, hospitals, municipalities, families | Care budgets, public programmes, self-pay | Can the solution fit safely into daily care? |
| Preventive and healthy-ageing solutions | Municipalities, insurers, healthcare groups, consumers | Public programmes, private budgets, self-pay | Who has enough incentive to pay before illness occurs? |
Demographic statistics are a strong starting point for your Japan analysis, not the conclusion.
Follow the buyer, not the population
One of the most common mistakes we see with non-Japanese companies is starting with the end-user.
“My product helps elderly people, therefore Japan should be interesting.”
Perhaps. But the user may have no role in the purchasing decision. For care technology, the economic buyer might be a large care provider trying to reduce staff workload. A care manager may influence product selection. A specialist welfare-equipment company may sit between manufacturer and user. A municipality may fund an implementation programme. Families may pay directly for another category of product.
The Japanese Long-Term Care Insurance system covers a defined range of services and welfare equipment. For designated welfare equipment, rental is the general principle, with selected products available through purchase arrangements. Users generally pay 10%, 20% or 30% depending on income. That creates a very different commercial model from simply selling a device to a consumer.
Reimbursement determines your entire Japan strategy
Healthcare and elderly care also sit inside different payment systems. A medical device or IVD intended for use in insured medical care requires a separate health insurance coverage procedure after the regulatory route has been addressed. Japan’s Ministry of Health, Labour and Welfare maintains specific insurance application categories and procedures for new medical devices and IVDs.
Care technology follows another logic. Some welfare equipment is covered by Long-Term Care Insurance. Other products may be purchased from provider budgets, supported through government or prefectural programmes, or paid for privately. A technically excellent solution therefore can face a weak commercial case if nobody has a realistic budget from which to buy it.
This should be resolved early. Do not wait until after regulatory work, localisation and partner discussions to ask who pays.
Where Japan is actively looking for solutions
Japan is not passive about the consequences of ageing. The Ministry of Health, Labour and Welfare and the Ministry of Economy, Trade and Industry have defined priority areas for care technology. The revised framework, in operation since April 2025, covers fields including transfer support, mobility, toileting, monitoring and communication, bathing and care-operation support. Newer priorities include functional training, food and nutrition management, and dementia support. In the summer of 2026, improved diabetes care also made the list.
That is useful intelligence for companies aiming for the Japan Silver Economy. It tells you where Japanese policymakers and care organisations see persistent operational problems. It does not mean that every technology addressing one of those problems will receive reimbursement or achieve rapid adoption. Japan rewards evidence, workflow fit and preparation.
Testbeds can be valuable, if you know what you are testing
Japan has unusually interesting opportunities for real-world testing in ageing and care. Kanagawa Prefecture’s ME-BYO Living Lab.
The Kanagawa ME-BYO Living Lab is an initiative by Kanagawa Prefecture, Japan. It matches companies with real-world test fields—like local communities and workplaces—to verify and evaluate the effectiveness of health and “ME-BYO” (better health/preventative care) products and services. for example, connects companies with real environments for testing health-related products and services. One documented project brought together a company, Tokai University, hospitals and elderly-care facilities to evaluate a gait-analysis technology for rehabilitation and fall prevention.
Yokohama has also developed a Living Lab model in which citizens, companies, universities, NPOs and government organisations work together in real living environments to develop and evaluate solutions.
There are national mechanisms too. AMED has continued to fund evidence generation for care technologies, including projects involving monitoring sensors and systems designed to improve indirect work in day-care operations. For you, this can be extremely useful.
Please always remember: A successful pilot is not a sale.
Before entering a testbed, we would want answers to several questions:
- Who is the potential commercial buyer?
- What result would make that buyer move forward?
- Which budget could eventually fund adoption?
- Who owns the decision after the pilot?
- What evidence is missing today?
- What happens during the 90 days after the test finishes?
If those questions have not been answered properly, you still have homework to undertake.
Japan can work for overseas AgeTech companies
There are cases showing how a foreign company can use partnerships and field testing to build its position. JETRO documented the US company Tellus You Care, which established a Japanese entity in 2020 for its contactless remote-monitoring technology. Before that, the company worked with NTT DOCOMO and Kobe City on a trial at an elderly-care facility. JETRO’s case study describes how access to care facilities, local feedback, investors and public support helped the company adapt its approach to Japan.
The key here is the sequence:
local relationship → real-world validation → user feedback → commercial learning → broad adoption discussions.
JETRO’s more recent review of the Japan Silver Economy and nursing sector also notes that overseas companies commonly enter through distribution partnerships with Japanese companies. It identifies adoption cost as a continuing barrier for care technology. That combination is very Japanese: genuine interest in technology, accompanied by serious scrutiny of who will implement it, support it and pay for it.
Technology must fit the care workflow
The care sector faces practical issues involving labour availability, workload, safety, documentation, communication, mobility, dementia care and home support. Recent Japanese policy reflects that reality. Care technology is being promoted partly to reduce staff burden and improve productivity while maintaining the quality of care. This means your sales discussion may need to change.
A monitoring system should not be sold simply because its sensor is more advanced. You need to show exact data demonstrating that it reduces unnecessary room checks, improves response times, integrates with existing routines, creates useful information for caregivers, and does not create another screen that staff need to monitor.
The product may be excellent.
How adaptable it is to existing workflows determines whether it gets used.
Five questions before you invest seriously in Japan
Before committing a strategic budget for market entry in Japan, I would ask:
1. What specific Japanese problem are you solving?
“Ageing” is not a problem statement. Falls, medication management, dementia-related wandering, rehabilitation, caregiver workload and early detection are.
2. Who has the authority and budget to buy?
Separate user, influencer, buyer, payer and gatekeeper.
They may be five different people or organisations.
3. Which payment route applies?
Medical reimbursement, Long-Term Care Insurance, provider CAPEX, municipal funding, subsidy programmes and private payment lead to very different strategies.
4. What evidence will the Japanese buyer need?
International data may open the first meeting. Local usability, workflow and economic evidence heavily influence the success of your project.
5. Who will take you through the Japanese organisation?
A distributor, strategic partner, care provider, clinical champion or local representative may be required. Choose according to what objectively makes business sense, not simply according to who answers your first email or speaks the best English.
So, is Japan’s Silver Economy a useful target for your company?
Possibly. The demographic case is undeniable. The Japanese government is actively addressing care productivity, prevention, dementia, rehabilitation and technology adoption. Real-world validation environments exist. Large healthcare and care organisations are looking for solutions.
But that is still not enough to be successful with the Japan Silver Economy. You need a product that solves a recognised Japanese problem, evidence that survives scrutiny, a buyer with budget, a workable payment route and somebody capable of moving the project through the Japanese organisation.
Japan rewards preparation.
Here is the actual good news. Japan is a demanding market! That means there are many barriers to overcome, and all your poorly prepared competitors will not stand a chance. This is your opportunity: Prepare well, commit and don’t look back!
Where Biosector can help
Biosector works with overseas health and life science companies that have a serious reason to investigate Japan. We can help assess the commercial opportunity, identify relevant buyer groups, map Japanese target organisations, find suitable partners, open senior-level discussions and support the commercial development of qualified opportunities.
We do not perform regulatory submissions, clinical-trial management, MAH services or routine distribution. Where those capabilities are needed, we help you find your best specialist partner. If you have a technology, product or service that may have a place in Japan’s Silver Economy, book a meeting or send us an email here.
We are happy to discuss your Japanese opportunity with you and help you decide whether it warrants your investment.
Comments are closed